Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1706-1712

  Leu, Kirsten M ^a   Ostruszka, Leo J ^a   Shewach, Donna ^a   Zalupski, Mark ^a   Sondak, Vernon ^a   Sybil Biertnann, J ^a   Lee, Julia Shin Jung ^a   Couwlier, Carol ^a   Palazzolo, Krisinda ^a   Baker, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ANGIOSARCOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER THERAPY; CELL CULTURE; CELL STRAIN MCF 7; COLONY FORMATION; CYTOTOXICITY; DRUG ACTIVITY; DRUG RESPONSE; EWING SARCOMA; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; NERVE SHEATH TUMOR; OSTEOSARCOMA; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; RETROPERITONEAL CANCER; REVIEW; SARCOMA; SIDE EFFECT; UTERUS SARCOMA; ADULT; AGED; ARTICLE; BONE TUMOR; DRUG ADMINISTRATION; DRUG INTERACTION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SOFT TISSUE TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TAXOIDS;

EID: 2442635522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.043     Document Type: Review

References (34)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Anonymous: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 350:1647-1654, 1997
3. Zalupski MM, Baker LH: Systemic adjuvant chemotherapy for soft tissue sarcomas. Hematol Oncol Clin North Am 9:787-800, 1995
4. th ed). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 388-415
5. Shewach DS, Hahn TM, Chang E, et al: Metabolism of 2′,2′- difluror-2′-deoxycutidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223, 1994
6. Huang P, Chubb S, Hertzel LW, et al: Action of 2′,2′- difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
7. Ross DD, Cuddy P: Molecular effects of 2′,2′- difluorodeoxycytidine (gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 48:1619-1630, 1994
8. Okuno S, Edmonson J, Mahoney M, et al: Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225-3229, 2002
9. Svancarova L, Blay JY, Judson IR, et al: Gemcitabine in advanced adult soft-tissue sarcomas: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:556-559, 2002
10. Merimsky O, Meller I, Flusser G, et al: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study. Cancer Chemother Pharmacol 45:177-181, 2000
11. Spath-Schwalbe E, Genvresse I, Koschuth A, et al: Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11:325-329, 2000
12. Patel SR, Gandhi V, Jenkins J, et al: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489, 2001
13. Bissery MC, Nohynek G, Sanderink G, et al: Docetaxel (Taxotere): A review of preclinical and clinical experience: Part 1: Preclinical experience. Anticancer Drugs 6:339-355, 1995
14. Verweij J, Lee SM, Ruka W, et al: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2081-2086, 2000
15. Edmonson JH, Ebbert LP, Nascimento AG, et al: Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 19:574-576, 1996
16. Kostler WJ, Brodowicz T, Attems Y, et al: Docetaxel as rescue medication in anthracycline- and if osfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial. Ann Oncol 12:1281-1288, 2001
17. van Hoesel QG, Verweij J, Catimel G, et al: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult: EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 5:539-542, 1994
18. Baker LH, Hirth JS, Carson E, et al: Cytochrome P4503A activity as a predictor of docetaxel toxicity and response. Proc Am Soc Clin Oncol 17:186, 1998 (abstr718)
19. Spiridonidis CH, Laufman LR, Jones J, et al: Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 16:3866-3873, 1998
20. Georgoulias V, Kouroussis C, Androulakis N, et al: Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. J Clin Oncol 17:914-920, 1999
21. Hensley ML, Maki R, Venkatraman E, et al: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 20:2824-2831, 2002
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
25. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
26. Patel SR, Vadhan-Raj S, Burgess MA, et al: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcoma. Am J Clin Oncol 21:317-321, 1998
27. Grunewald R, Abbruzzese JL, Tarassoff P, et al: Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262, 1991
28. Grunewald R, Kantarjian H, Keating MJ, et al: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990
29. Theodossiou C, Cook JA, Fisher J, et al: Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 12:825-832, 1998
30. Kroep JR, Giaccone G, Tolis C, et al: Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small cell lung cancer cell lines. Br J Cancer 83:1069-1076, 2000
31. Ricotti L, Tesei A, De Paola F, et al: In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 9:900-905, 2003
32. Smorenburg CH, Sparreboom A, Botenbal M, et al: Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. Eur J Cancer 37:2310-2323, 2001
33. Dunsford ML, Mead GM, Bateman AC, et al: Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10:943-947, 1999
34. Kouroussis C, Kakolyris S, Mavroudis D, et al: A phase I study of weekly docetaxel and gemctiabine in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 20:273b, 2001